Clinical trials: Antipsychotic
Schizophrenia
A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics
This multicenter study assessed the effects of 24 weeks of basmisanil treatment on cognition and functioning of stable schizophrenia participants treated with antipsychotics.
- Trial name
- NCT02953639
- Testing
- Basmisanil
- Where
- 37 sites in United States
- Volunteers
- 214 people
- Sponsor
- Hoffmann-La Roche
Alzheimer's Type Dementia
Music Therapy in Alzheimer's Disease
The primary purpose of the protocol is to demonstrate that the use of music therapy may make it possible to discontinue at least one of neuroleptic treatment in patients with AD or related symptoms complicated by behavioral…
- Trial name
- PRE-MUSICAL (NCT02020356)
- Testing
- Music therapy
- Where
- 7 sites in France
- Volunteers
- 35 people
- Sponsor
- University Hospital, Toulouse
Schizophrenia
Antipsychotic Effects of Probiotics and Prebiotics on Patients With Schizophrenia
In this study, investigators will evaluate the efficacy and related mechanism of probiotics and prebiotics as an add-on treatment in improving the antipsychotic induced psychotic syndrome, the cognitive impairment…
- Trial name
- NCT04291469
- Testing
- Probiotics（Live combined bifidobacteria, lactobacillus and maltodextrin tables), Prebiotics (Combined inulin and maltodextrin tables), maltodextrin
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Psychotic Disorder
The Role of Antidepressants or Antipsychotics in Preventing Psychosis
This is a randomized, controlled pilot study comparing the antidepressant fluoxetine with the second generation antipsychotic aripiprazole in approximately 10 subjects aged 12-25 at risk for developing psychosis.
- Trial name
- NCT01724372
- Testing
- Antidepressant, Antipsychotic
- Sponsor
- St. Luke's-Roosevelt Hospital Center
Schizophrenia, Renal Impairment
A Study of the Pharmacokinetics of ER OROS Paliperidone in Volunteers With Normal or Impaired Renal Function
The purpose of this study is to evaluate the pharmacokinetics of a single oral dose of 3 mg extended release paliperidone (ER OROSÃ' paliperidone) in patients with varying degrees of renal impairment (mild, moderate, and severe)…
- Trial name
- NCT00791401
- Testing
- ER OROS Paliperidone
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Depression
Risperidone and Suicidality in Major Depressive Disorder
The purpose of this trial is to investigate the efficacy of risperidone as an adjunct to an antidepressant treatment in the acute management of suicidality during an episode of major depressive disorder.
- Trial name
- NCT00167154
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Alabama at Birmingham
Schizophrenia
Long-Term Study of MP-214 in Patients With Schizophrenia
The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with schizophrenia.
- Trial name
- NCT01626872
- Testing
- MP-214 3mg, MP-214 6mg, MP-214 9mg
- Where
- 3 sites in Japan, South Korea and 1 more
- Volunteers
- 254 people
- Sponsor
- Tanabe Pharma Corporation
Schizophrenia
CATIE- Schizophrenia Trial
The CATIE Schizophrenia Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The schizophrenia trial is being conducted to determine the long-term effects and usefulness of…
- Trial name
- NCT00014001
- Testing
- perphenazine, olanzapine, quetiapine
- Where
- 54 sites in United States
- Volunteers
- 1,600 people
- Sponsor
- National Institute of Mental Health (NIMH)
Weight Gain
A Study on Induced Weight Gain During Atypical Antipsychotic Treatment and Its Management With Psychoeducational Programme
Olanzapine is an atypical antipsychotic agent indicated for the treatment of schizophrenia and moderate to severe manic episode. Olanzapine is among the many antipsychotic agents associated with weight gain .
- Trial name
- NCT00191828
- Testing
- olanzapine
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Metabolic Syndrome, Schizophrenia
Prevalence of the Metabolic Syndrome in SPR Taking Antipsychotics
The purpose of this study is to assess the cross-sectional prevalence of the metabolic syndrome in patients with schizophrenia taking antipsychotics.
- Trial name
- NCT00569504
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Seoul National Hospital
Urinary Tract Infections (UTIs), Urinary Tract Infection, Recurrent
Effects of Pomegranate Seed Oil Supplementation in Patients With Advanced Dementia
The goal of this clinical study is to learn if Pomegranate Seed Oil supplementation works to combat urinary tract infections, recurrenturinary tract infections, or pneumonia and contributes to the tapering or discontinuation of…
- Conditions
- Urinary Tract Infections (UTIs), Urinary Tract Infection, Recurrent, Antipsychotics Discontinuation, Antipsychotics Tapering
- Trial name
- NCT07432763
- Testing
- Pomegranate Seed Oil Supplementation in Palliative Care Patients with Advanced Dementia, Care-as-usual
- Where
- Greece
- Volunteers
- 18 people
- Sponsor
- Panhellenic Federation of Alzheimer's Disease and Related Disorders
Schizophrenia, Psychotic Disorders
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up
Cognitive enhancement is a primary goal in treating individuals with schizophrenia. Cognitive deficits are already present at the first break of the illness, seem to remain stable during early phases and noticeably influence…
- Trial name
- PAFIP2_nc1Y (NCT02534363)
- Testing
- Aripiprazole, Quetiapine, Ziprasidone
- Where
- Spain
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Schizophrenia
Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment
The objective of this study is to demonstrate that there is a benefit in switching chronic schizophrenic patients from conventional antipsychotic to olanzapine in terms of efficacy, neurological safety and patient's outcome.
- Trial name
- NCT00191555
- Testing
- olanzapine, haloperidol
- Where
- 62 sites in France
- Volunteers
- 360 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With Schizophrenia
Antipsychotic alone is limit to improve the overall outcome of schizophrenia and has a high discontinue rate.To solve these problems, we provide practical and available psychosocial intervention.
- Trial name
- ACPIOS (NCT00654576)
- Testing
- Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole, psychosocial intervention
- Where
- China
- Volunteers
- 1,400 people
- Sponsor
- Central South University
Clinical High-risk
A Study of Antipsychotics in Individuals at Clinical High-risk for Psychosis (the SHARP-2 Study)
The current study will improve knowledge on the effectiveness and safety of the use of antipsychotics at the prodromal phase and on factors influencing the outcome, and will eventually facilitate optimisation of individualised…
- Trial name
- NCT04010864
- Testing
- routine clinical treatment
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia
Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia
This study will examine the effects of ondansetron on auditory nerve activity in people with schizophrenia who are being treated with new antipsychotics.
- Trial name
- NCT00149734
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Colorado, Denver
Schizophrenia
iTBS for Increased Appetite Induced by Antipsychotics
Antipsychotics are prone to cause metabolic side effects, including weight gain, hyperglycemia, insulin resistance, hyperlipidemia and so on, leading to a 2-3 times higher risk of death in patients with schizophrenia compared to…
- Trial name
- NCT05783063
- Testing
- Active iTBS
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Central South University
Schizophrenia
Antipsychotic Discontinuation in High-risk Subjects
Would be there any difference in dopamine synthesis between remitted clinical high risk subjects for psychosis and healthy control? What would happen to dopamine synthesis after antipsychotic discontinuation in clinical high risk…
- Trial name
- NCT01758887
- Where
- South Korea
- Volunteers
- healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Schizophrenia
Efficacy and Safety of a Long Acting Anti-Psychotic Versus Placebo in Patients With Schizophrenia
The purpose of this study is to determine the efficacy (how well the drug works), safety, and side effects of paliperidone palmitate compared to placebo in the treatment of the symptoms of schizophrenia in adults.
- Trial name
- NCT00101634
- Testing
- Paliperidone palmitate
- Volunteers
- 518 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorder
Validity of the Spanish Version of Subjective Well-being Under Neuroleptics Scale (SWN-K) in Patients With Schizophrenia
Observational, short-term prospective, multicenter study to assess psychometric properties of the Spanish version of SWN-K scale in patients with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- SWN-K (NCT00749970)
- Where
- 14 sites in Spain
- Volunteers
- 100 people
- Sponsor
- AstraZeneca